Parental Refusal of Vitamin K and Neonatal Preventive Services: A Need for Surveillance

Lauren H Marcewicz1,2,3, Joshua Clayton4,5, Matthew Maenner4,6

  • 1Centers for Disease Control and Prevention, Epidemic Intelligence Service, Atlanta, GA, USA. lauren.marcewicz@gmail.com.

Insights

Parental refusal of injectable vitamin K for newborns is higher at birthing centers than hospitals. Common reasons include belief in its necessity and preference for natural birth processes.

Area of Science:

  • Pediatrics
  • Public Health
  • Neonatal Care

Background:

  • Vitamin K deficiency bleeding (VKDB) is a preventable infant coagulopathy.
  • Injectable vitamin K at birth is the standard prophylaxis.
  • Parental refusal of this intervention prompted investigation.

Purpose of the Study:

  • To investigate parental refusal rates of injectable vitamin K in Tennessee.
  • To identify reasons for refusal and associated factors.
  • To compare refusal rates between hospital births and birthing centers.

Main Methods:

  • Chart reviews at Nashville-area hospitals (2011-2013) and Tennessee birthing centers (2013).
  • Identification of infants whose parents refused vitamin K prophylaxis.
  • Surveys administered to parents to determine reasons for refusal.

Main Results:

  • In 2013, 3.0% of hospital infants and 31% of birthing center infants did not receive vitamin K due to refusal.
  • Primary refusal reasons: belief in necessity (53%) and natural birth preference (36%).
  • 66% of families refusing vitamin K also refused other newborn preventive services.

Conclusions:

  • Injectable vitamin K refusal is significantly higher in birthing centers compared to hospitals.
  • Refusal is associated with a broader pattern of rejecting other preventive newborn care.
  • Enhanced surveillance and targeted strategies are needed to address vitamin K refusal.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
628
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
586
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K